

# **mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026**

<https://marketpublishers.com/r/M724C0219685EN.html>

Date: September 2025

Pages: 217

Price: US\$ 2,999.00 (Single User License)

ID: M724C0219685EN

## **Abstracts**

The mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry,

Forecast and outlook (2024-2031) Scope:

## Major Highlights

This report delivers a comprehensive overview of the mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement

and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### MTOR INHIBITORS IN ONCOLOGY

- mTOR better known as the mammalian target of rapamycin is a protein kinase that governs many cellular functions. It forms two specific multiprotein complexes, specified mTOR complexes 1 and 2 (mTORC1 and mTORC2).
- Each complex plays master roles in cellular regulation. mTORC1 controls multiple anabolic pathways, which can also include protein synthesis, lipogenesis, ribosome production, and nucleotide synthesis, all of them is important for cell and tissue growth. mTORC1 also suppresses autophagy which is a primary catabolic process. mTORC1 suppresses the production of lysosomes, the organelles responsible for autophagy.
- Also, it alters the activity and subcellular localization of cellular regulations by phosphorylation of the proteins involved in these pathways.
- An elementary characteristic of cancer cells is their ability to nurture continued proliferation in the absence of growth-promoting signals.
- This characteristic is successful in part by genetic events that cause exceptional activation of mTORC1 signaling: mTORC1 signaling is hyperactive in most of the cancers. Inhibiting mTORC1 signaling has, therefore, captivating great attention from cancer researchers as a potential therapy.
- As both the bioavailability and solubility of rapamycin are low, more soluble rapamycin derivatives analogs called rapalogs are developed.
- Emerging economies and increase in adoption of mTOR inhibitors for various types of cancers have proved to provide excellent opportunities in the field. Increase in the diagnosed population in a variety of cancers, about 1.7 million new cancer cases are expected to be diagnosed in 2018 and growing demand for the mTOR inhibitors at patient level certainly can foresee a positive growth of the market.
- However, to avail these benefits, researchers and investors have to concentrate on cost employed for research and development, complexity in the mechanism of action.
- To overcome the challenges due to changes, make cancer cells resistant to a drug, researchers have to develop next-generation therapies. The first generation of mTOR inhibitors like Afinitor, Torisel were approved more than a decade ago, recent developments are noticed to overcome the resistance of these drugs in cancer.
- More than 60 molecules are under development in various stages. Majority of the products are in the mid-level stage of development. BN-107 of Bionovo, ME-344 of MEI Pharma are in Phase 2 whereas DS-3078 of Daiichi, CC-115 of Celgene are in the early clinical stage of development. About 18 molecules are in the preclinical stage of development some of them include SB2602 of S\*BIO, OXA 01 of Astellas, XL388 of Exelixis.

## I would like to order

Product name: mTOR Inhibitors in Oncology 2018 – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/M724C0219685EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M724C0219685EN.html>